Qiagen (NYSE:QGEN – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Profitability
This table compares Qiagen and Pluri’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Qiagen | 4.23% | 13.92% | 8.40% |
Pluri | -3,551.49% | -2,778.13% | -83.61% |
Institutional and Insider Ownership
70.0% of Qiagen shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Qiagen | $1.98 billion | 4.73 | $83.59 million | $0.40 | 105.20 |
Pluri | $678,000.00 | 61.33 | -$20.89 million | ($5.60) | -0.96 |
Qiagen has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Qiagen has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Qiagen and Pluri, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Qiagen | 0 | 7 | 3 | 0 | 2.30 |
Pluri | 0 | 0 | 0 | 0 | 0.00 |
Qiagen currently has a consensus target price of $48.42, indicating a potential upside of 15.06%. Given Qiagen’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Qiagen is more favorable than Pluri.
Summary
Qiagen beats Pluri on 11 of the 14 factors compared between the two stocks.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.